Prostate‐specific antigen‐based prostate cancer screening: Past and future

@article{Alberts2015ProstatespecificAP,
  title={Prostate‐specific antigen‐based prostate cancer screening: Past and future},
  author={Arnout R. Alberts and Ivo G. Schoots and Monique J. Roobol},
  journal={International Journal of Urology},
  year={2015},
  volume={22}
}
Prostate‐specific antigen‐based prostate cancer screening remains a controversial topic. Up to now, there is worldwide consensus on the statement that the harms of population‐based screening, mainly as a result of overdiagnosis (the detection of clinically insignificant tumors that would have never caused any symptoms), outweigh the benefits. However, worldwide opportunistic screening takes place on a wide scale. The European Randomized Study of Screening for Prostate Cancer showed a reduction… 

Screening for prostate cancer: moving forward in the molecular era.

TLDR
New screening tests and/or methods with increased specificity could reduce the number of men undergoing prostate biopsy - thus alleviating patients from the anxiety and the distress experienced by an unnecessary (negative) biopsy and minimizes the healthcare cost.

Re: Prostate‐specific antigen‐based prostate cancer screening: Past and future

  • S. Birkeland
  • Medicine
    International journal of urology : official journal of the Japanese Urological Association
  • 2016
TLDR
Although SDM approaches probably improve patients’ knowledge and decision-making, decrease PSA test utilization and perhaps would benefit the physician during a lawsuit, the effect on patient satisfaction and complaint behavior merits further investigation.

Towards a better Diagnosis of Prostate Cancer: A Review of Prostate Cancer Screening Tests

  • Arslaan Javaeed
  • Medicine
    International Journal of Contemporary Medical Research [IJCMR]
  • 2018
TLDR
Various modalities along with their pros and cons available for the diagnosis and screening of prostate cancer are represented.

Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review

TLDR
A review of research papers published from 2009 to 2019 reporting biomarkers that identified or differentiated benign prostatic hyperplasia (BPH) from prostate cancer concludes that this validation will come through the use of multivariate panels which can assess the value of biomarker candidates in combination with clinical parameters as part of a risk prediction calculator.

Risk of Prostate Cancer–related Death Following a Low PSA Level in the PLCO Trial

TLDR
Substantial risk disparities suggest appropriate screening intervals could depend on race/ethnicity, and five-year screening intervals may be appropriate for the 45% of men with PSA ≤ 1 ng/mL.

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

TLDR
The ability of the biomarker panel to perform better than PSA alone in men with BPH, thus preventing unnecessary biopsies is demonstrated, and potential to limit false negatives in aggressive cancers is indicated.

Current guidelines for prostate cancer screening: A systematic review and minimal core proposal.

TLDR
A minimum core of conducts was established that may be useful in the daily practice of the physician for screening for prostate cancer and there are differences between them.

Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities

TLDR
The potential of nanotechnology is increasingly being realized, especially in prostate cancer research, and the most updated information is provided on the recent methods of prostate cancer screening, imaging and treatment modalities, with special emphasis on nanotheranostics and multifunctional nanoconstructs.

Editorial Comment to Prostate‐specific antigen‐based prostate cancer screening: Past and future

  • S. Sakamoto
  • Medicine
    International journal of urology : official journal of the Japanese Urological Association
  • 2015
TLDR
Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.
...

References

SHOWING 1-10 OF 127 REFERENCES

Beyond PSA: The Next Generation of Prostate Cancer Biomarkers

TLDR
The current state of prostate cancer biomarker research, including the PSA revolution, its impact on early cancer detection, the recent advances in biomarker discovery, and the future efforts that promise to improve clinical management of this disease are reviewed.

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.

  • E. BaschT. Oliver R. Nam
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
There is evidence to suggest that men with longer life expectancy may benefit from PSA testing, and several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern.

Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010

  • Kazuto ItoS. Naito K. Okihara
  • Medicine
    International journal of urology : official journal of the Japanese Urological Association
  • 2010
TLDR
PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.

Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies

TLDR
Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives.

Screening for prostate cancer.

TLDR
It is insufficient, at present, to recommend routine population screening because of the lack of evidence that this would improve either survival or the quality of men’s lives, according to most reviews of the scientific evidence.
...